ClinicalTrials.gg
CompletedNCT05999071Updated Aug 21, 2023

Coriandrum Sativum Seeds Improve Memory, Alleviate Anxiety and Depression, and Enhance Sleep Quality in University Students: A Randomized Controlled Trial

An interventional study of Coriandrum sativum seeds in Memory Disorders, Anxiety Depression and Sleep, sponsored by The Hashemite University. Completed at 1 site in Jordan. Open to participants aged 19 Years to 23 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-21.

Sponsored by The Hashemite University · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Mar 2022, registered Aug 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
19 Years to 23 Years
Sex
All
01

Study summary

C. sativum could potentially serve as a memory enhancer for university students. It is considered a preferable option to stimulant drugs due to its safety profile. Additionally, C. sativum may have positive effects on anxiety, depression, and sleep quality. However, it is important to note that the current body of research on the effects of oral C. sativum on the brain and nervous system is limited, and further studies are necessary to fully understand its potential benefits. Thus, this study aims to assess the impact of oral C. sativum on memory performance, anxiety, depression, and sleep quality in university students.

Read the detailed description

Coriander, scientifically known as Coriandrum sativum L (C. sativum), is an ancient herb that belongs to the Apiaceae family. It has a rich history of more than 3,000 years of use in both culinary and medicinal practices. While originally native to Mediterranean regions, coriander is now cultivated in various countries worldwide. In traditional medicine, all parts of the coriander plant have been consumed and utilized to address gastrointestinal ailments like anorexia, dyspepsia, flatulence, diarrhea, pain, and vomiting. In Jordanian traditional medicine, C. sativum has been valued for its anticonvulsant, antidepressant, sedative, and anxiolytic properties. Studies have reported diverse health benefits associated with C. sativum seeds and leaves, including antioxidant, diuretic, cholesterol-lowering, anxiolytic, sedative-hypnotic, and anticonvulsant activities. Notably, the main component of C. sativum, linalool, along with γ-terpinene and α-pinene, exhibit various neuropharmacological effects, such as anti-anxiety, sedative, anticonvulsant, and anti-Alzheimer's disease properties. Additionally, C. sativum seeds are recognized as a valuable source of vitamins, lipids, and minerals like potassium, calcium, phosphorus, magnesium, sodium, and zinc.

Several studies have indicated the positive effects of C. sativum on memory, anxiety, and depression. In a specific study, the aqueous extract derived from the seeds of C. sativum demonstrated significant reductions in monoamine oxidase-B (MAO-B) activity over time, suggesting its primary role in exerting antidepressant-like effects. Another study reported that the administration of C. sativum leaves improved memory performance and hindered the aging process in rats in a dose-dependent manner. Furthermore, it was observed that C. sativum leaves reversed memory impairments induced by scopolamine and diazepam, while also significantly reducing brain cholinesterase activity and serum total cholesterol levels. Another study evaluated the effects of the ethanolic extract of C. sativum seeds on learning in second-generation mice. Although the plant extract did not enhance learning in the short term following training, it did show improvements in long-term learning. Additionally, in an animal model of anxiety, the effects of different doses (10 mg/kg, 25 mg/kg, 50 mg/kg, and 100 mg/kg administered intraperitoneally) of the aqueous extract of C. sativum seeds were evaluated in terms of motor activity and neuromuscular function. In the elevated plus-maze test, the 100 mg/kg dose of the seeds' aqueous extract exhibited anxiolytic effects by increasing the time spent in and the number of entries into the open arms.

Anxiety, depression, and sleep disorders are prevalent among university students, and these conditions can have a considerable impact on their memory function. Consequently, there has been a rise in the use of stimulant drugs among university students as a means to enhance memory performance and attention, despite the fact that such use is unapproved and non-therapeutic which might be associated with several side effects. As a result, there is a growing interest among neuroscience researchers to identify cognitive-enhancing drugs that can be safely used by healthy individuals without adverse effects.

Given the information provided, it is suggested that C. sativum could potentially serve as a memory enhancer for university students. It is considered a preferable option to stimulant drugs due to its safety profile. Additionally, C. sativum may have positive effects on anxiety, depression, and sleep quality. However, it is important to note that the current body of research on the effects of oral C. sativum on the brain and nervous system is limited, and further studies are necessary to fully understand its potential benefits. Thus, this study aims to assess the impact of oral C. sativum on memory performance, anxiety, depression, and sleep quality in university students.

02

Conditions studied

  • Memory Disorders
  • Anxiety Depression
  • Sleep

Keywords

  • Coriandrum sativum
  • memory performance
  • anxiety
  • depression
  • sleep
03

In context

Memory Disorders

373 studies on the registry are indexed under Memory Disorders; 67 are open to participants now.

This study's enrollment of 86 is above the median of 72 across 298 interventional studies indexed under Memory Disorders.

Browse Memory Disorders studies →

Lead sponsor

The Hashemite University is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 23 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female university Student.
  • 19-23 of age

Exclusion criteria

Exclusion Criteria:

  • Medical diseases.
  • Psychiatric disorders.
  • Using any form of medication (including complementary and alternative medicines).
  • Pregnant and lactating individuals.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Coriandrum sativum group

    500 mg of C. sativum (capsules) were administered twice daily

    Dietary Supplement: Coriandrum sativum seeds

  • Placebo comparator
    control group

    500 mg of starch (capsules) were administered twice daily

    Dietary Supplement: Coriandrum sativum seeds

Interventions

  • Dietary supplementCoriandrum sativum seeds

    Each group consisted of 50 students. In the C. sativum group, dried powdered seeds of C. sativum were administered, while in the control group, starch was provided as a placebo. Both the C. sativum and placebo capsules were identical in shape, color, and outer packaging to maintain the blinding of the participants.

    Also known as: Coriandrum

06

What researchers measure

Primary outcomes

  1. Memory performance

    Prospective and Retrospective Memory Questionnaire was performed

    Time frame: 30 days

Secondary outcomes

  1. Anxiety and depression

    Hospital Anxiety and Depression Scale was perfomed

    Time frame: 30 days

  2. Sleep quality

    Pittsburgh Sleep Quality Inventory questionnaire was perfoemed

    Time frame: 30 days

07

Study locations

1 site
  • Faculty of Pharmaceutical Sciences
    Zarqa, 13133, Jordan
08

References and documents

Individual participant data

Plan to share: No — All participants data will be hidden

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Jul 2022, 4 months.

Of 129 non-industry interventional studies with no phase under Memory Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 53. This study's 4 months is below that.

Counting every sponsor, half of 138 studies reached it within 35 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2023
First posted
Aug 21, 2023
StartActual
Mar 1, 2022
Primary completionActual
Jul 1, 2022
CompletionActual
Jul 1, 2022
Last update
Aug 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05999071
Lead sponsor
The Hashemite University
Responsible party
Abdelrahim Alqudah (Assisstant professor, The Hashemite University) — Principal investigator
First posted
Aug 21, 2023
Start date
Mar 1, 2022
Primary completion
Jul 1, 2022
Completion
Jul 1, 2022
Last update
Aug 21, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion